Cytokines in Sjögren's syndrome: Potential therapeutic targets

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 945-948

  Roescher, Nienke ^a,b   Tak, Paul P ^b   Illei, Gabor G ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BELIMUMAB; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; MONOCLONAL ANTIBODY; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SALIVARY GLAND DISEASE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ARTICLE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; HUMANS; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953727883     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.115378     Document Type: Review

References (32)

1. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis 2009;15:519-26.
2. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285-96.
3. Shiozawa S, Shiozawa K, Shimizu S, et al. Immunoreactive circulating alpha-interferon is low in Sjögren's syndrome. Br J Rheumatol 1990;29:50-2.
4. Ferraccioli GF, SalaffiF, De Vita S, et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996;14:367-71.
5. Shiozawa S, Morimoto I, Tanaka Y, et al. A preliminary study on the interferon-alpha treatment for xerostomia of Sjögren's syndrome. Br J Rheumatol 1993;32:52-4. (Pubitemid 23053592)
6. Cummins JM, Krakowka GS, Thompson CG. Systemic effects of interferons after oral administration in animals and humans. Am J Vet Res 2005;66:164-76.
7. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998;18:255-62. (Pubitemid 28176009)
8. Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999;19:943-51.
9. Cummins MJ, Papas A, Kammer GM, et al. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-93. (Pubitemid 36988314)
10. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
11. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
12. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
13. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
14. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008;67:1437-43.
15. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004.
16. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285-96.
17. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 2006;103:2770-5.
18. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
19. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis 2009;15:519-26.
20. Ittah M, Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008;38:1058-64.
21. Navarra S, Guzman R, Gallacher A, et al. Belimumab, a Blys-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Philadelphia, Pennsylvania, USA: American College of Rheumatology Meeting, 2009.
22. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
23. Illei G, Shirota Y, Yarboro C, et al. Tocilizumab in systemic lupus erythematosus - safety, preliminary efficacy and impact on circulating plasma cells. Arthritis Rheum 2010; 62:542-52.
24. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006;31:109-16. (Pubitemid 44166289)
25. Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs 2008;9:515-22. (Pubitemid 351677906)
26. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
27. Kikly K, Liu L, Na S, et al. The IL-23/Th (17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-5.
28. Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77.
29. Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43.
30. Sakai A, Sugawara Y, Kuroishi T, et al. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181:2898-906.
31. Kok MR, Yamano S, Lodde BM, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther 2003;14:1605-18.
32. Lodde BM, Mineshiba F, Wang J, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006;65:195-200.